Skip to content

Oncternal Therapeutics, Inc.

CIK 0001260990

← back to feed
Revenue (TTM)
$2.04M
−47.3% YoY Q3 Nov 2024
Net Income (TTM)
−$35.27M
+10.6% YoY Q3 Nov 2024
EPS Diluted (TTM)
−$11.93
+20.1% YoY Q3 Nov 2024
Gross Margin
46.5%
Q3 Nov 2024
Operating Margin
-1,797.0%
Q3 Nov 2024
Net Margin
-1,726.5%
Q3 Nov 2024
Free Cash Flow (TTM)
−$33.06M
Q3 Nov 2024
Cash
$13.08M
Q3 Nov 2024
Total Debt
—
Q3 Nov 2024
Shares Outstanding
2.96M sh
Q3 Nov 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings